Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
- D. Baeten, J. Sieper, H. Richards
- MedicineNew England Journal of Medicine
- 23 December 2015
Secukinumab at a subcutaneous dose of 150 mg, with either sub cutaneous or intravenous loading, provided significant reductions in the signs and symptoms of ankylosing spondylitis at week 16, and was sustained through 52 weeks.
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
- P. Mease, R. Fleischmann, D. M. van der Heijde
- MedicineAnnals of the Rheumatic Diseases
- 13 August 2013
Rapid improvements in the signs and symptoms of PsA, including joints, skin, enthesitis, dactylitis and nail disease were observed across both CZP dosing regimens, independent of prior TNF inhibitor exposure.
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
- R. Landewé, J. Braun, J. Sieper
- MedicineAnnals of the Rheumatic Diseases
- 6 September 2013
CZP rapidly reduced the signs and symptoms of axSpA, with no new safety signals observed compared to the safety profile of CZP in RA, and similar improvements were observed across C ZP dosing regimens, and in AS and nr-axSpA patients.
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate…
- P. Emery, A. Deodhar, H. Tyrrell
- MedicineAnnals of the Rheumatic Diseases
- 20 May 2010
Rituximab (at 2×500 mg and 2×1000 mg) plus MTX significantly improved clinical outcomes at week 24, which were further improved by week 48, and no significant differences in either clinical or safety outcomes were apparent between the rituxIMab doses.
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
- J. Smolen, J. Braun, D. M. van der Heijde
- MedicineAnnals of the Rheumatic Diseases
- 8 June 2013
The task force defined the treatment target for SpA as remission or, alternatively, low disease activity, being aware that the evidence base is not strong and needs to be expanded by future research.
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and…
- M. Ward, A. Deodhar, L. Caplan
- MedicineArthritis & Rheumatology
- 1 February 2016
To provide evidence‐based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
- P. Mease, M. Genovese, A. Nirula
- MedicineNew England Journal of Medicine
- 11 June 2014
Bdalumab significantly improved response rates among patients with psoriatic arthritis; responses were sustained through week 52 and larger studies of longer duration are necessary to assess adverse events.
Bone mass measurement and bone metabolism in rheumatoid arthritis: a review.
- A. Deodhar, A. Woolf
- Medicine, BiologyBritish Journal of Rheumatology
- 1 April 1996
Bone histomorphometric studies suggest that the periarticular osteopenia in RA could be related to increased bone turnover locally, whereas generalized osteoporosis could be due to a global negative remodelling balance.
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and…
- M. Ward, A. Deodhar, L. Caplan
- MedicineArthritis care & research
- 21 August 2019
To update evidence‐based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).
Measurement of hand bone mineral content by dual energy x-ray absorptiometry: development of the method, and its application in normal volunteers and in patients with rheumatoid arthritis.
- A. Deodhar, J. Brabyn, P. Jones, M. Davis, A. Woolf
- MedicineAnnals of the Rheumatic Diseases
- 1 October 1994
A new, sensitive and reproducible technique of measurement of hand bone mineral content by DXA, has been developed and this method has been applied to normal volunteers and patients with RA and hand BMC showed an inverse correlation with age and disease duration.
...
...